Treatment of coronary high risk individuals with statins;STATINBEHANDLING VED HOY RISIKO FOR KORONARSYKDOM

Tidsskrift for den Norske Laegeforening

Volumn 116, Issue 12, 1996, Pages 1479-1481

  Holme, Ingar ^a  

^a Livsforsikringsselskapenes M   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAVASTATIN; DRUG DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; SIMVASTATIN;

ATHEROSCLEROSIS; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG COST; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MORTALITY; SHORT SURVEY; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; MALE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UNITED KINGDOM;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; HUMANS; LOVASTATIN; MALE; PRAVASTATIN; RISK FACTORS; SCOTLAND; SIMVASTATIN;

EID: 0029934527     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. Shepherd J, Cobbe S, Ford I, Isles CG. Lorimer R, Mac Farlane PW et al. Prevention of coronary heart disease with Pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
3. Furberg CD, Adams AP jr., Applegate WB, Byington RP, Espeland MA, Hartwell T et al. Effect of lovastatin on early carotid atherosclerosis and cardiovasular events (ACAPS). Circulation 1994; 90: 1679-87.
4. Gouid LA, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look into old data. Circulation 1995; 91: 2274-82.
5. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol 1995; 76: 10C-17C.
6. The Pravastatin Multinational Study Group for cardiac risk patients. Effects of pravastatin in patients with serum cholesterol levels from 5.2 to 7 8 mmol/l (200-300 mg/dl) plus two additional risk factors. Am J Cardiol 1993; 72: 1031-7.
7. Jukema JW, Bruschke AVG, van Bowen AJ, Reiber HC, Bal ET, Zwinderman AH et al. Effects of lipid lowering by Pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol level. The regression growth evaluation statin study (REGRESS). Circulation 1995; 91. 2528-40.
8. Salonen R, Nyyssönen K, Porkkala E, Rumukainen J, Belder R, Park JS. Kuopio Atherosclerosis Prevention Study (KAPS) A population-based primary preventive trial of the effect of LDL-lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-64.
9. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis m the coronary arteries (PLAC I): reduction in atherosclerotic progression and clinical events. J Am Coll Cardiol 1995; 26: 1133-9.
10. Crouse JR, Byington RP, Bond GM, Espeland MA, Craven TE, Sprinkle JW et al. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455-9.
11. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatmant L, Wang XM et al. Effect of pravastatin on outcome after cardiac transplantation. N Engl J Med 1995; 333: 621-7.
12. Bradford RH, Shear CL, Chremos AN, Dujome C, Franklin FA, Hesney M et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 43-9.
13. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633-8.
14. Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-38.